RxDoctor Payments Data

John Englehardt, MD

Clinical Cardiac Electrophysiology · Raleigh, NCNPI 1154320307

Payments from drug & device makers

$5,704in general payments, 2019–2025

Across 215 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$628
  • Biotronik Inc.$615
  • Irhythm Technologies, Inc.$572
  • Boston Scientific$552
  • E.r. Squibb & Sons, L.L.C.$457
  • Medtronic$448
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,704100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,704 in reported general payments places this provider in the 15th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

See all clinical cardiac electrophysiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$135,320
Medicare patients
382
Services billed
1,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban245$248,208
JardianceEmpagliflozin16$20,943
XareltoRivaroxaban37$20,537
MultaqDronedarone Hcl18$16,114
Propafenone Hcl ErPropafenone Hcl28$5,229
Propafenone Hcl101$4,371
Flecainide Acetate67$2,986
Metoprolol Succinate141$2,978
Amiodarone Hcl131$1,896
Mexiletine Hcl12$1,052
Metoprolol Tartrate92$616
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$474
Spironolactone36$388
Losartan Potassium43$382
Carvedilol58$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$273$248,208245 claims
Boehringer IngelheimJardiance$204$20,94316 claims
Johnson & JohnsonXarelto$179$20,53737 claims
Sanofi-aventis U.S. LLCMultaq$628$16,11418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

Other clinical cardiac electrophysiology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →